tiprankstipranks
Trending News
More News >
I-MAB (IMAB)
NASDAQ:IMAB
US Market
Advertisement

I-MAB (IMAB) AI Stock Analysis

Compare
397 Followers

Top Page

IMAB

I-MAB

(NASDAQ:IMAB)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 4o)
Rating:45Neutral
Price Target:
The overall stock score of 45 reflects I-MAB's substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
Positive Factors
Strong Cash Position
A strong cash position provides I-MAB with the financial flexibility to fund operations and strategic initiatives through 2028, supporting long-term growth.
Clinical Progress
Advancing clinical trials on schedule enhances I-MAB's pipeline credibility and potential market impact, reinforcing its position in immuno-oncology.
Leadership Strengthening
Strengthening leadership with experienced directors and forming an R&D Committee can drive strategic focus and innovation, boosting long-term prospects.
Negative Factors
Profitability Challenges
Persistent profitability issues indicate structural financial weaknesses, potentially limiting reinvestment capacity and long-term sustainability.
Negative Cash Flows
Negative cash flows highlight operational inefficiencies and could constrain future growth investments, impacting long-term financial health.
Revenue Volatility
Erratic revenue trends suggest market and operational instability, which can undermine investor confidence and hinder strategic planning.

I-MAB (IMAB) vs. SPDR S&P 500 ETF (SPY)

I-MAB Business Overview & Revenue Model

Company DescriptionI-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
How the Company Makes MoneyI-MAB primarily generates revenue through partnerships and collaborations with other pharmaceutical companies for the development and commercialization of its drug candidates. The company may receive upfront payments, milestone payments, and royalties from these partnerships as its drug candidates progress through clinical trials and reach the market. Additionally, I-MAB might gain revenue from licensing its proprietary technologies and intellectual property to other entities. Significant partnerships with global pharmaceutical companies facilitate the advancement of its pipeline, contributing to its earnings potential.

I-MAB Financial Statement Overview

Summary
I-MAB faces substantial financial challenges, particularly in terms of profitability and cash flow generation. Although the company benefits from a strong liquidity position and low leverage, its ability to generate positive earnings and cash flows remains a concern. The volatility in revenue and consistent losses highlight the need for strategic adjustments to improve financial performance.
Income Statement
20
Very Negative
The company's income statement indicates significant challenges, with substantial negative net income and EBIT margins over recent years. Although there was a positive revenue figure in 2023, the revenue growth has been erratic, with a substantial decline from 2020 to 2022 followed by a modest recovery. Gross profit margins have been inconsistent, which, coupled with negative net profit and EBIT margins, underscores profitability issues.
Balance Sheet
50
Neutral
The balance sheet shows a strong equity base relative to liabilities, with a debt-to-equity ratio remaining low due to minimal debt levels. However, the equity ratio has been declining, indicating diminishing equity relative to total assets. The company maintains a significant cash position, which is a positive sign of liquidity.
Cash Flow
30
Negative
Cash flow analysis reveals persistent negative free cash flows, indicating challenges in generating sufficient cash from operations. The absence of operating cash flow data for 2023 makes it difficult to assess the recent cash generation ability. Historical trends show negative operating cash flow, impacting the overall cash flow position negatively.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.99M0.0027.64M-221.56M88.03M1.54B
Gross Profit3.99M0.0027.64M-248.80M41.59M1.54B
EBITDA-303.56M-373.45M-1.21B-1.94B-2.06B168.31M
Net Income-341.81M-162.26M-1.47B-2.51B-2.33B470.92M
Balance Sheet
Total Assets232.68M212.68M2.61B4.07B5.63B6.33B
Cash, Cash Equivalents and Short-Term Investments184.39M173.40M2.29B3.45B4.28B4.79B
Total Debt3.78M3.88M18.89M74.99M112.45M13.60M
Total Liabilities14.80M11.52M894.81M1.07B1.04B706.65M
Stockholders Equity217.88M201.16M1.72B3.01B4.59B5.63B
Cash Flow
Free Cash Flow0.00-52.72M-72.86M-1.15B-1.00B425.55M
Operating Cash Flow0.00-52.67M-72.70M-1.10B-973.09M433.56M
Investing Cash Flow0.00-136.01M102.52M458.38M-727.21M-201.90M
Financing Cash Flow0.00-335.00K7.57M42.36M593.92M3.44B

I-MAB Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price3.48
Price Trends
50DMA
3.68
Negative
100DMA
2.75
Positive
200DMA
1.83
Positive
Market Momentum
MACD
-0.10
Positive
RSI
42.31
Neutral
STOCH
8.55
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMAB, the sentiment is Neutral. The current price of 3.48 is below the 20-day moving average (MA) of 3.99, below the 50-day MA of 3.68, and above the 200-day MA of 1.83, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 42.31 is Neutral, neither overbought nor oversold. The STOCH value of 8.55 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IMAB.

I-MAB Risk Analysis

I-MAB disclosed 91 risk factors in its most recent earnings report. I-MAB reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We face significant risks related to the transition of our business focus to the U.S. market and our business and prospects may be materially and adversely affected. Q4, 2023
2.
We face risks associated with the divestiture of the Greater China assets and business operations to I-Mab Hangzhou. Q4, 2023
3.
Evolvement in the U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates. Q4, 2023

I-MAB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
17.76B14.4022.13%23.25%64.46%
55
Neutral
40.83B-189.82-4.71%47.14%66.69%
52
Neutral
3.49B-15.45-26.84%32.38%33.47%
45
Neutral
$281.93M-22.37%-100.00%72.53%
44
Neutral
115.33M-0.69-58.44%-31.23%14.92%
42
Neutral
1.52K>-0.01-95.23%42.16%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IMAB
I-MAB
3.48
2.33
202.61%
ACHV
Achieve Life Sciences
3.01
-1.76
-36.90%
VOR
Vor Biopharma
33.62
19.44
137.09%
ADAG
Adagene
1.96
-0.28
-12.50%
CNTX
Context Therapeutics
0.91
-0.95
-51.08%
ZURA
Zura Bio
2.41
-1.66
-40.79%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 31, 2025